Wednesday, March 16, 2022 10:24:59 AM
Mississauga-based Profound Medical develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids and palliative pain treatment in Canada, Germany, the United States and Finland, with its chief offering being the prostate cancer-targeted ultrasound ablation technology TULSA-PRO.
Loe’s latest analysis comes after Profound reported its fourth quarter financial results, along with its 2021 year-end totals.
“Commentary was centered on the firm’s FDA/EMA-approved MR-guided prostate-focused ultrasound ablation platform TULSA-PRO and ongoing marketing/clinical/reimbursement activities to drive adoption,” Loe said. “Momentum is building in early F2022 after predictably sluggish operations in F2021.”
Profound recorded $1 million in revenue, a 65.6 per cent year-over-year drop, with the full amount coming from recurring revenue and nothing from capital equipment sales. However, Loe noted that the company maintained its expectations of 40 new TULSA-PRO installations in 2022, combatting what was a slow end to the fiscal year. (All figures in US dollars.)
The company also posted total operating expenses of approximately $10.2 million, representing a 69 per cent year-over-year increase, a number that Loe expects to go up with the company starting to enroll 201 patients in its CAPTAIN trial.
According to Loe, the company ended the quarter with $67.2 million in cash and equivalents available, which should be enough to support its ongoing clinical and commercial efforts pertaining to TULSA-PRO.
“Despite facing COVID-19 headwinds that impacted the pace of new U.S. TULSA-PRO installations in the first three quarters of 2021, the opportunity that we see for the technology remains intact,” said Arun Menawat, Profound’s CEO and Chairman in the company’s March 3 press release. “Indeed, with many of the leading hospitals in the U.S. being early adaptors of the technology, and clinicians already treating an unrivaled variety of prostate disease patients, we are well ahead of where competing treatment technologies were in their first two years post-launch. TULSA-PRO installations in the United States increased significantly in Q4-2021, and that trend has continued so far in the current quarter. We believe this bodes well for potential higher revenue growth in 2022.”
Despite the company finishing 2021 at a six per cent loss from a revenue perspective, Loe expects tailwinds from TULSA-PRO’s continued progression to help the company’s bottom line sooner rather than later, as he forecasts a 441 per cent jump to $37.2 million in revenue for 2022, with approximately 72.2 per cent of the revenue mix coming from TULSA-PRO capital equipment and accessories. Looking ahead to 2023, Loe forecasts an 85 per cent year-over-year increase to $68.7 million, with the TULSA-PRO categories accounting for 70.9 per cent of the projected revenue mix.
Loe then forecasts the company’s total revenue to jump into nine figures at $108.7 million in 2024 for a 58 per cent year-over-year increase (72.7 per cent coming from the TULSA-PRO categories), beginning a steep revenue curve that culminates in a 2028 projection of $297.9 million in revenue, with TULSA-PRO and its accessories accounting for 81.9 per cent of the revenue mix.
Meanwhile, 2022 sees Loe forecasting positive EBITDA for Profound for the first time, with the $3.04 million projection introducing an eight per cent margin, which he forecasts to jump to 30 per cent ($20.8 million in EBITDA) in 2023. From there, Loe forecasts the margin to continue rising, potentially reaching as high as 57 per cent ($170.3 million in EBITDA) by 2028.
Finally, from 2022 on, Loe forecasts stable gross margins of 45 per cent for capital equipment and 73 per cent for its accessories.
From a valuation perspective, Loe introduces an EV/EBITDA multiple in 2022 at 14.5x, along with a P/E multiple of greater than 30x.
Overall, Loe notes his investment thesis regarding Profound is relatively unchanged from before.
“Even though topline performance reflected no capital equipment sales in FQ421 owing to pandemic challenges, we believe that retrospective focus on trailing sales data as a baseline for future TULSA-PRO/Sonalleve adoption is to miss the fact that signals of recovering growth trajectory are already apparent, and should be reflected in financial data as early as FQ122,” Loe said.
Profound Medical’s stock price has had a pronounced drop over the last 12 months, reporting a 62.8 per cent loss in that time. Since the release of Loe’s analysis, the stock has dropped a further 12.3 per cent, hitting C$10/share on Tuesday, a long way from the 52-week high of $28.77/share the company saw a year ago.
Recent PROF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2024 08:30:09 PM
- Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum • GlobeNewswire Inc. • 05/06/2024 08:15:00 PM
- Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow • GlobeNewswire Inc. • 04/22/2024 08:15:00 PM
- Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference • GlobeNewswire Inc. • 04/09/2024 11:45:00 AM
- Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 09:05:00 PM
- Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference • GlobeNewswire Inc. • 03/04/2024 09:30:00 PM
- Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure • GlobeNewswire Inc. • 02/27/2024 12:45:00 PM
- Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow • GlobeNewswire Inc. • 02/15/2024 09:30:00 PM
- Profound Medical Announces Non-Brokered Private Placement • GlobeNewswire Inc. • 01/16/2024 09:30:00 PM
- Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues • GlobeNewswire Inc. • 01/03/2024 09:15:00 PM
- Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares • GlobeNewswire Inc. • 12/28/2023 03:40:00 AM
- Profound Medical Announces Proposed Public Offering of Common Shares • GlobeNewswire Inc. • 12/27/2023 09:15:00 PM
- Profound Medical to Participate in the Stifel 2023 Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 12:45:00 PM
- Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting • GlobeNewswire Inc. • 11/03/2023 12:00:00 PM
- Profound Medical Announces Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/02/2023 08:05:00 PM
- Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow • GlobeNewswire Inc. • 10/19/2023 08:30:00 PM
- Profound Medical 2023 Virtual Analyst & Investor Day Agenda • GlobeNewswire Inc. • 10/10/2023 08:30:00 PM
- Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost • GlobeNewswire Inc. • 09/25/2023 08:05:00 PM
- Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13 • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/19/2023 08:45:00 PM
- Profound Medical Announces At-the-Market Offering of up to US$30,000,000 • GlobeNewswire Inc. • 09/06/2023 11:23:52 PM
- Profound Medical Announces Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/09/2023 08:05:00 PM
- Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow • GlobeNewswire Inc. • 08/02/2023 08:30:00 PM
- Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases • GlobeNewswire Inc. • 06/02/2023 05:40:00 PM
- Profound Medical Announces Upcoming Investor Events • GlobeNewswire Inc. • 05/30/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM